Menu
MorphoSys US

Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.

Taking Big Steps

Visit our Online Magazine

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

Latest
news

19/10/2020
MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for...
Read Media Release
13/10/2020
MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds
Read Media Release
13/10/2020
Ad hoc: MorphoSys AG Launches an Offering of approx. EUR 325 Million...
Read Media Release
30/09/2020
MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020
Read Media Release
17/09/2020
MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and...
Read Media Release
17/09/2020
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/...
Read Media Release
18/08/2020
National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix...
Read Media Release
05/08/2020
MorphoSys Reports Second Quarter and First Half 2020 Results
Read Media Release
01/08/2020
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with...
Read Media Release
01/08/2020
MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in...
Read Media Release

September 29, 2020
Webcast & Conference Call
MorphoSys & Incyte Tafasitamab Expert Event

Full details

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No